Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lancet on multivitamins

This article was originally published in The Tan Sheet

Executive Summary

Panel recommendations from the National Institutes of Health provide an opportunity for physicians to educate patients about nutrition, according to an editorial in The Lancet May 27. The independent panel determined May 17 that there currently is too little evidence to support - or advise against - the use of multivitamin and mineral supplements for the prevention of chronic diseases (1"The Tan Sheet" May 22, 2006, p. 6). Herein lays the chance for physicians to become better informed counselors and caregivers, The Lancet says. "Consumers need to know about the supplements and foods they choose to buy. But there is a clear role for informed medical advice to patients here too." The Lancet adds that the escalating obesity epidemic, and its impact on chronic diseases, amplifies the need for nutritional counseling to figure more prominently in medical school curricula. "Doctors must tackle their patients not only about how much they eat, but also what they eat," the journal reports...

You may also be interested in...



More Multivitamin Research Needed To Show Disease Prevention – NIH Panel

Members of an independent NIH panel evaluating the safety and effectiveness of multivitamin/minerals (MVMs) hope that a draft report containing their recommendations will spur action on research efforts for the supplement category

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel